In summary, SFAS ameliorates CHF by restoring impaired fatty acid oxidation and replenishing ATP via the activation of the AMPK/PGC-1α/SIRT3 signaling pathway, while concurrently suppressing oxidative stress. The gene discussed is SIRT3; the disease is congestive heart failure.